Dr. Weeks’ Comment: Cancer STEM cells are now being targeted and the new is good for people with cancer. The leaders in oncology know that the standard of care – chemotherapy and radiation therapy – is making people worse.
“…Neoadjuvant chemotherapy has been shown to lead to an increase in markers of cancer stem cells (CSCs) in primary breast cancer…”
“… In most patients with small cell lung cancer (SCLC), tumors initially respond to first line chemotherapy, but subsequently experience rapid recurrence. In previously reported research, preclinical models of other cancers demonstrated that CSC populations are increased following chemotherapy, and that inhibitors of FAK and PI3K/mTOR have been shown to preferentially target CSCs. FAK and PI3K/mTOR inhibitors may be particularly valuable in a SCLC setting, where CSCs may be strong mediators of recurrence…”
Verastem Presents Encouraging Scientific Data on the Preferential Targeting of Cancer Stem Cells at the 2015 American Association of Cancer Research Annual Meeting
Published on April 22, 2015
Verastem, Inc. (NASDAQ:VSTM) , focused on discovering and developing drugs to treat cancer by the targeted killing of cancer STEM cells, today announced the presentation of scientific data at the 2015 American Association of Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA.
“The data presented provide continued evidence that VS-6063, VS-4718 and VS-5584 effectively target cancer STEM cells, reduce tumor initiating capability and prolong the anti-tumor response to standard of care chemotherapy in preclinical models of multiple tumor types. The results from these studies support both ongoing and planned clinical trials. We believe these agents have the potential to be used alongside standard-of-care treatments, to address both the cancer STEM cells and the bulk tumor cells, as a strategy to potentially generate more durable responses for patients with cancer.”
Verastem, and its collaborators, are presenting these scientific data in support of Verastem’s programs targeting cancer stem cells through inhibition of the focal adhesion kinase (FAK; VS-6063 and VS-4718) and PI3K/mTOR (VS-5584) signaling pathways. Research on the FAK and PI3K/mTOR signaling pathways has revealed critical roles for each in cancer STEM cell survival and disease progression. Cancer STEM cells have tumor-initiating capability, are particularly resistant to chemotherapy and can mediate tumor recurrence both locally and at metastatic sites.
Details for the data presentations at AACR are as follows:
Title: FAK inhibitors VS-6063 and VS-4718 target cancer stem cells: Implications for TNBC sequential and combination therapies
Summary: Neoadjuvant chemotherapy has been shown to lead to an increase in markers of cancer stem cells (CSCs) in primary breast cancer. The presence of the ALDH cancer stem cell marker in residual cancer tissue in lymph nodes at surgery after neoadjuvant chemotherapy has been associated with a significantly worse prognosis following primary treatment. It is also evident that stem-like features of tumor cells are present in metastatic breast cancer indicating that targeting of CSCs may be valuable in metastatic disease. Verastem’s CSC inhibitors, VS-6063 and VS-4718, diminished CSCs in vitro, ex vivo and in xenograft models in contrast to paclitaxel or cisplatin treatment which enriched CSCs. Consistent with the notion that CSCs are responsible for cancer relapse after chemotherapy, VS-6063 and VS-4718 substantially delayed tumor growth following cessation of paclitaxel or cisplatin treatment in models of triple negative breast cancer. Additionally, both VS-6063 and VS-4718 inhibited metastatic outgrowth and/or induced regression of metastases after primary tumor resection, whereas metastases progressed in all animals in the control group. These results support the clinical investigation of the CSC-targeting agents VS-6063 and VS-4718 in certain breast cancer settings to potentially delay time to relapse and improve the treatment outcome.
A copy of the oral presentation is available at http://bit.ly/12otlcV
Title: FAK and PI3K/mTOR inhibitors target cancer stem cells: Implications for SCLC treatment strategies Date and time:
Summary: In most patients with small cell lung cancer (SCLC), tumors initially respond to first line chemotherapy, but subsequently experience rapid recurrence. In previously reported research, preclinical models of other cancers demonstrated that CSC populations are increased following chemotherapy, and that inhibitors of FAK and PI3K/mTOR have been shown to preferentially target CSCs. FAK and PI3K/mTOR inhibitors may be particularly valuable in a SCLC setting, where CSCs may be strong mediators of recurrence. In this study, the antitumor activity of FAK and PI3K/mTOR inhibitors (VS-4718 and VS-5584, respectively) were investigated in SCLC xenograft models in vivo.
In the preclinical models studied, the standard-of-care agents, cisplatin and etoposide, enriched the proportion of CSCs. In direct contrast, both VS-5584 and VS-4718 reduced SCLC CSCs in vivo when combined with chemotherapy. VS-5584 and VS-4718 also delayed tumor regrowth after treatment with these cytotoxic agents in SCLC xenograft models of switch maintenance therapy. The preferential targeting of CSCs in preclinical SCLC models provides an important rationale for clinical development of VS-5584 and VS-4718 in combination with chemotherapy to potentially lengthen the time to relapse and improve the treatment outcome for patients with SCLC.
A copy of the poster presentation is available at http://bit.ly/12otlcV
Title: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells, which are enriched by standard of care chemotherapy
Summary: Malignant pleural mesothelioma (MPM) is an aggressive tumor in the lining of the lung and median overall survival with standard of care chemotherapy is only 12 months. This poor prognosis may be attributable at least in part to CSCs which are resistant to chemotherapy and can mediate cancer recurrence and progression. FAK has been shown to play an essential role in the survival, self-renewal and tumor-initiating capability of CSCs.
In the preclinical models and patient biopsies studied, two standard-of-care agents, pemetrexed and platinum, enrich the proportion of CSCs. In direct contrast, the FAK inhibitor, VS-6063, markedly reduced CSCs in models of mesothelioma. In addition, in tumors that are low in the biomarker merlin, marked bulk tumor reduction was observed. In a switch maintenance model, VS-6063 treatment also delayed tumor regrowth following cisplatin plus pemetrexed treatment in vivo. These data provide strong rationale for the current clinical testing of VS-6063 in Verastem’s registration-directed COMMAND trial, evaluating VS-6063 in a maintenance setting to potentially prolong response to front line chemotherapy in patients with mesothelioma.
A copy of the poster presentation is available at http://bit.ly/12otlcV
Title: Targeting Focal Adhesion Kinase is a novel approach to therapy of high-risk, Ikaros-mutant acute B-cell lymphoblastic leukemia
This research includes work on VS-4718 and was presented by collaborators. A copy of the poster presentation is available at http://bit.ly/12otlcV
About VS-6063 VS-6063 (defactinib) is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Research by Robert Weinberg, Ph.D., scientific cofounder and chair of Verastem’s Scientific Advisory Board, and Verastem has demonstrated that FAK activity is critical for the growth and survival of cancer stem cells. VS-6063 is currently being studied in the registration-directed COMMAND trial in mesothelioma (www.COMMANDmeso.com), a “Window of Opportunity” study in patients with mesothelioma prior to surgery, a Phase 1/1b study in combination with paclitaxel in patients with ovarian cancer, a trial in patients with Kras-mutated non-small cell lung cancer and a trial evaluating the combination of VS-6063 and VS-5584 in patients with relapsed mesothelioma. VS-6063 has been granted orphan drug designation in the U.S. and EU for use in mesothelioma.
About VS-4718 VS-4718 is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). VS-4718 is currently being studied in a Phase 1 dose escalation study in patients with advanced cancers.
About VS-5584 VS-5584 is an orally available compound that has demonstrated potent and highly selective activity against class 1 PI3K enzymes and dual inhibitory actions against mTORC1 and mTORC2. In preclinical studies, VS-5584 has been shown to reduce the percentage of cancer stem cells and induce tumor regression in chemotherapy-resistant models. Verastem is currently conducting a dose escalation trial of VS-5584 in patients with advanced solid tumors as a single agent and a combination trial of VS-5584 and VS-6063 in patients with relapsed mesothelioma. VS-5584 has been granted orphan drug designation in the U.S. and EU for use in mesothelioma.